PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

Dhiraj Yadav; Walter G. Park; Evan L. Fogel; Liang Li; Suresh T. Chari; Ziding Feng; William E. Fisher; Christopher E. Forsmark; Christie Y. Jeon; Aida Habtezion; Phil A. Hart; Steven J. Hughes; Mohamed O. Othman; Jo Ann S. Rinaudo; Stephen J. Pandol; Temel Tirkes; Jose Serrano; Sudhir Srivastava; Stephen K. Van Den Eeden; David C. Whitcomb; Mark Topazian; Darwin L. Conwell

doi:10.1097/MPA.0000000000001170

PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

Dhiraj Yadav
, Walter G. Park
, Evan L. Fogel
, Liang Li
, Suresh T. Chari
, Ziding Feng
, William E. Fisher
, Christopher E. Forsmark
, Christie Y. Jeon
, Aida Habtezion
, Phil A. Hart
, Steven J. Hughes
, Mohamed O. Othman
, Jo Ann S. Rinaudo
, Stephen J. Pandol
, Temel Tirkes
, Jose Serrano
, Sudhir Srivastava
, Stephen K. Van Den Eeden
, David C. Whitcomb

Mark Topazian, Darwin L. Conwell

Producción científica: Article › revisión exhaustiva

99 Citas (Scopus)

Resumen

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

Idioma original	English
Páginas (desde-hasta)	1229-1238
Número de páginas	10
Publicación	Pancreas
Volumen	47
N.º	10
DOI	https://doi.org/10.1097/MPA.0000000000001170
Estado	Published - nov 1 2018

Nota bibliográfica

Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.

Financiación

PROCEED is part of the CPDPC, a cooperative agreement grant funded by the NCI (National Cancer Institute) and the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases). The participating sites, organizational structure of the CPDPC, and its studies are provided elsewhere in this issue of the journal29 and at http://cpdpc.mdanderson.org. ‡‡‡Division of Research, Kaiser Permanente Northern California, Oakland, CA; §§§Departments of Cell Biology and Physiology; and ||||||Human Genetics, University of Pittsburgh, UPMC, Pittsburgh, PA. Received for publication July 21, 2018; accepted August 24, 2018. Address correspondence to: Dhiraj Yadav, MD, MPH, Division of Gastroenterology and Hepatology, University of Pittsburgh Medical Center, 200 Lothrop St, M2, C-wing, Pittsburgh, PA 15213 (e‐mail: [email protected]). This study was supported by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases under the following award numbers: U01DK108288 (S.T.C., M.T.), U01DK108300 (W.G.P., A.H.), U01DK108306 (D.C.W., D.Y.), U01DK108314 (C.Y.J., S.J.P.), UO1DK108300 (C.E.F., S.J.H.), U01DK108323 (E.L.F., T.T.), U01DK108326 (W.E.F., M.O.O.), U01DK108327 (P.H., D.L.C.), and U01DK108328 (Z.F., L.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D.C.W. is a consultant for AbbVie, Regeneron, and Ariel Precision Medicine, and may have equity in Ariel Precision Medicine. The other authors declare no conflict. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/MPA.0000000000001170

Financiadores	Número del financiador
CPDPC
National Childhood Cancer Registry – National Cancer Institute
National Institute of Diabetes and Digestive and Kidney Diseases	U01DK108306, U01DK108328, U01DK108327, U01DK108323, U01DK108326, U01DK108314, U01DK108300, U01DK108288
National Institute of Diabetes and Digestive and Kidney Diseases

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Hepatology
Endocrinology

Acceder al documento

10.1097/MPA.0000000000001170

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer'. En conjunto forman una huella única.

Citar esto

Yadav, D., Park, W. G., Fogel, E. L., Li, L., Chari, S. T., Feng, Z., Fisher, W. E., Forsmark, C. E., Jeon, C. Y., Habtezion, A., Hart, P. A., Hughes, S. J., Othman, M. O., Rinaudo, J. A. S., Pandol, S. J., Tirkes, T., Serrano, J., Srivastava, S., Van Den Eeden, S. K., ... Conwell, D. L. (2018). PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer. Pancreas, 47(10), 1229-1238. https://doi.org/10.1097/MPA.0000000000001170

@article{38c36284c2174fa890a1d5b162d83a37,

title = "PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer",

abstract = "Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.",

keywords = "alcohol, biorepository, cohort, genetic, pancreas, tobacco",

author = "Dhiraj Yadav and Park, \{Walter G.\} and Fogel, \{Evan L.\} and Liang Li and Chari, \{Suresh T.\} and Ziding Feng and Fisher, \{William E.\} and Forsmark, \{Christopher E.\} and Jeon, \{Christie Y.\} and Aida Habtezion and Hart, \{Phil A.\} and Hughes, \{Steven J.\} and Othman, \{Mohamed O.\} and Rinaudo, \{Jo Ann S.\} and Pandol, \{Stephen J.\} and Temel Tirkes and Jose Serrano and Sudhir Srivastava and \{Van Den Eeden\}, \{Stephen K.\} and Whitcomb, \{David C.\} and Mark Topazian and Conwell, \{Darwin L.\}",

year = "2018",

month = nov,

day = "1",

doi = "10.1097/MPA.0000000000001170",

language = "English",

volume = "47",

pages = "1229--1238",

number = "10",

}

Yadav, D, Park, WG, Fogel, EL, Li, L, Chari, ST, Feng, Z, Fisher, WE, Forsmark, CE, Jeon, CY, Habtezion, A, Hart, PA, Hughes, SJ, Othman, MO, Rinaudo, JAS, Pandol, SJ, Tirkes, T, Serrano, J, Srivastava, S, Van Den Eeden, SK, Whitcomb, DC, Topazian, M & Conwell, DL 2018, 'PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer', Pancreas, vol. 47, n.º 10, pp. 1229-1238. https://doi.org/10.1097/MPA.0000000000001170

PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies: Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer. / Yadav, Dhiraj; Park, Walter G.; Fogel, Evan L. et al.
En: Pancreas, Vol. 47, N.º 10, 01.11.2018, p. 1229-1238.

Producción científica: Article › revisión exhaustiva

TY - JOUR

T1 - PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies

T2 - Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer

AU - Yadav, Dhiraj

AU - Park, Walter G.

AU - Fogel, Evan L.

AU - Li, Liang

AU - Chari, Suresh T.

AU - Feng, Ziding

AU - Fisher, William E.

AU - Forsmark, Christopher E.

AU - Jeon, Christie Y.

AU - Habtezion, Aida

AU - Hart, Phil A.

AU - Hughes, Steven J.

AU - Othman, Mohamed O.

AU - Rinaudo, Jo Ann S.

AU - Pandol, Stephen J.

AU - Tirkes, Temel

AU - Serrano, Jose

AU - Srivastava, Sudhir

AU - Van Den Eeden, Stephen K.

AU - Whitcomb, David C.

AU - Topazian, Mark

AU - Conwell, Darwin L.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

AB - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.

KW - alcohol

KW - biorepository

KW - cohort

KW - genetic

KW - pancreas

KW - tobacco

UR - https://www.scopus.com/pages/publications/85055078667

UR - https://www.scopus.com/pages/publications/85055078667#tab=citedBy

U2 - 10.1097/MPA.0000000000001170

DO - 10.1097/MPA.0000000000001170

M3 - Article

C2 - 30325862

AN - SCOPUS:85055078667

SN - 0885-3177

VL - 47

SP - 1229

EP - 1238

JO - Pancreas

JF - Pancreas

IS - 10

ER -